Glucose-dependent Insulinotropic Polypeptide (GIP)
Evidence: B/C — Meaningful Human EvidenceNeuroendocrine / Appetite-Energy Balance Signaling
Evidence Snapshot
What this grade covers
Two independent human intervention studies (Christensen/Vedtofte/Holst/Vilsboll/Knop 2011 clamp study, N=10; PMID 2647605 fasting-state T2DM infusion) directly demonstrating glucose-dependent insulin/glucagon physiology, plus a receptor-pharmacology source (Deacon 2006) establishing GIP(1-42) != GIP(3-42). Tirzepatide's and Retatrutide's own clinical outcomes are EXCLUDED entirely -- both are engineered receptor agonists, ANALOGUE_PROGRAM_CONTEXT only. Overall page grade: B/C.
Regulatory Context
Native GIP is an endogenous human hormone and is not itself an FDA-approved drug product. Tirzepatide (Mounjaro/Zepbound) is a separately regulated, FDA-approved engineered dual GIP/GLP-1 receptor agonist; Retatrutide remains investigational. Neither approval nor investigational status extends to native GIP.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
The first-identified incretin hormone, released from intestinal K cells after eating.
Why are researchers interested in it?
Studied for its central role in glucose-dependent regulation of insulin and glucagon secretion, and as the physiological basis for engineered GIP-receptor-agonist drugs.
What does the evidence look like?
Two independent human clamp/infusion intervention studies directly demonstrating its native pharmacology.
Biggest things to know
GIP's effects on insulin and glucagon are glucose-dependent; GIP(1-42) is inactivated by DPP-4 to GIP(3-42), which does not meaningfully antagonize intact GIP at normal levels.
What don't we know yet?
Whether native GIP alone (not engineered analogues) has any therapeutic weight or glucose effect outside short clamp studies -- no long-term native-GIP trial exists.
Research Takeaway
Intravenous GIP given during hypoglycemic, euglycemic, and hyperglycemic clamps in 10 healthy men produces glucose-dependent effects on glucagon and insulin secretion -- greater glucagon response during hypoglycemia -- establishing GIP as a bifunctional, glucose-dependent regulator.
Evidence boundary: GIP's own native pharmacology, not evidence for any engineered GIP-receptor-agonist drug.
See all 3 evidence claims →Quick Summary
Glucose-dependent insulinotropic polypeptide (GIP) is the body's original incretin hormone, released after eating to help regulate insulin and glucagon. It is distinct from Tirzepatide and Retatrutide, engineered drugs that also activate the GIP receptor.
Mechanism & Research Overview
Glucose-dependent insulinotropic polypeptide (GIP) is the body's original incretin hormone, released after eating to help regulate insulin and glucagon. It is distinct from Tirzepatide and Retatrutide, engineered drugs that also activate the GIP receptor.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Intravenous GIP given during hypoglycemic, euglycemic, and hyperglycemic clamps in 10 healthy men produces glucose-dependent effects on glucagon and insulin secretion -- greater glucagon response during hypoglycemia -- establishing GIP as a bifunctional, glucose-dependent regulator.
Does not establish
Evidence boundary: GIP's own native pharmacology, not evidence for any engineered GIP-receptor-agonist drug.
Supported
IV GIP infusion in the fasting state is insulinotropic in people with type 2 diabetes.
Does not establish
Evidence boundary: Native physiology only.
Supported
GIP(1-42) is inactivated by DPP-4 cleavage to GIP(3-42); GIP(3-42) does not physiologically antagonize intact GIP(1-42) at normal circulating concentrations in humans.
Does not establish
Evidence boundary: Establishes GIP(1-42) != GIP(3-42) boundary; not a claim about engineered GIP-receptor agonist drugs.
Sources: GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Two live, widely-discussed engineered GIP-receptor-agonist drugs (Tirzepatide, Retatrutide) exist and their substantial clinical-trial outcomes must never be attributed to native GIP.Safety Consideration
Only short clamp/infusion-study tolerability data exists; no long-term human safety record for native GIP administration.
Research Areas Being Studied
Research areas discussed on this page reflect the Neuroendocrine / Appetite-Energy Balance Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans (2011):
- GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations (2006):
- Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus (1989):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans | 2011 | 10 healthy men | IV GIP during hypoglycemic, euglycemic, and hyperglycemic clamps produced glucose-dependent effects on glucagon and insulin secretion, with greater glucagon response during hypoglycemia -- establishing GIP as a bifunctional, glucose-dependent regulator. | ||
| GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations | 2006 | Human ex vivo / clamp pharmacology | GIP(1-42) is inactivated by DPP-4 cleavage to GIP(3-42); GIP(3-42) does not physiologically antagonize intact GIP(1-42) at normal circulating concentrations in humans. | No source link available | |
| Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus | 1989 | Type 2 diabetes patients, fasting state | IV GIP infusion in the fasting state is insulinotropic in people with type 2 diabetes. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Native GIP is distinct from Tirzepatide and Retatrutide -- those engineered drugs' trial results do not apply here.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-28.
Follow research updates for Glucose-dependent Insulinotropic Polypeptide (GIP)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.